CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 7,500,000 shares of its common stock at a public offering price of $10.75 per share. All of the shares are being sold by Alnylam. The offering is expected to close on February 21, 2012, subject to customary closing conditions.
